Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe
 

TON - April 2020, Vol 13, No 2

TON April 2020, Vol 13, No 2 Cover

On April 3, 2020, the Association for Value-Based Cancer Care (AVBCC) held a webcast with healthcare experts representing major industry stakeholders to address the impact of the COVID-19 pandemic on oncology delivery systems and the management of patients with cancer.
The University of Chicago Cancer Center at Silver Cross Hospital, New Lenox, IL, is a satellite treatment center providing high-quality, university-based care in a community hospital setting.
San Francisco, CA—Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-­centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision-making process.
San Francisco, CA—Second-line treatment with a 3-drug regimen that included the PD-1 inhibitor nivolumab (Opdivo), the VEGF receptor antagonist ramucirumab (Cyramza), and chemotherapy with the taxane paclitaxel, showed durable and impressive response rates, regardless of PD-L1 expression, in patients with advanced gastric cancers.
The April issue of The Oncology Nurse-APN/PA (TON) is filled with important news for today’s oncology nurse.
San Francisco, CA—Positron emission tomography (PET) scanning targeted to detect prostate-specific membrane antigen (PSMA) is poised to overtake conventional imaging, according to presentations at the 2020 Genitourinary Cancers Symposium.
San Francisco, CA—Combining cabozantinib (Cabometyx) with atezolizumab (Tecentriq) induced responses in 32% of patients with metastatic castration-resistant prostate cancer (CRPC) who had soft-tissue progression after previous novel hormonal therapy.
San Francisco, CA—Cholangiocarcinoma (CCA), a type of biliary tract cancer, is a rare malignancy, with no FDA-approved medications specifically for this type of cancer. The current standard first-line treatment for patients with locally advanced or metastatic CCA is a chemotherapy combination of gemcitabine and cisplatin.
San Francisco, CA—Although there is a biological rationale that supports the “abscopal” effects of radiation therapy plus checkpoint immunotherapy in fighting cancer, this combination showed mixed results and no robust effects in patients with metastatic renal-cell carcinoma (RCC), according to results of 2 preliminary studies presented at the 2020 Genitourinary Cancers Symposium.

Results 1 - 9 of 9